Related Experiment Video
Updated: Jun 6, 2026
07:13
An Alternative and Validated Injection Method for Accessing the Subretinal Space via a Transcleral Posterior Approach
Published on: December 7, 2016
[Qualitative differences between ranibizumab from original and ready to use syringes]
1Augenklinik der Universität zu Lübeck, Universitätsklinikum Schleswig-Holstein, Ratzeburger Allee 160, Lübeck, Germany. salvatore.grisanti@uk-sh.de
Summary
Storing ranibizumab in plastic syringes reduces its binding affinity to VEGF-165 over time, especially with light and room temperature exposure. This impacts the biological efficacy of the antibody fragment.
Area of Science:
- Ophthalmology
- Pharmaceutical Science
- Biochemistry
Background:
- Ranibizumab is an antibody fragment used in treating neovascular eye conditions.
- The storage of ranibizumab in pre-filled plastic syringes is an emerging practice influenced by socioeconomic and legal factors.
- Understanding the stability and efficacy of ranibizumab in plastic syringes is crucial for clinical application.
Purpose of the Study:
- To investigate the impact of time, temperature, and light on ranibizumab stored in plastic syringes.
- To assess the quality and biological efficacy of ranibizumab after storage in plastic syringes.
- To compare the stability of ranibizumab in pre-sampled syringes with commercially available ready-to-use syringes.
Main Methods:
- Ranibizumab samples were stored in plastic tuberculin syringes under various conditions (temperature, light).
- Analyzed parameters included pH, protein stability, concentration, and binding affinity to VEGF-165 using ELISA.
- Compared pre-sampled syringes with commercially available ready-to-use ranibizumab syringes.
Main Results:
- Stored ranibizumab maintained stable pH.
- Protein concentration showed slight decreases over time, unaffected by light or room temperature.
- Binding affinity to VEGF-165 significantly decreased over time, with further reductions due to light and room temperature exposure.
Conclusions:
- Storage of ranibizumab in plastic syringes affects its biological efficacy.
- The binding affinity to VEGF-165 is compromised by storage duration and environmental factors.
- These findings add a new consideration to the choice between original vials and pre-sampled ranibizumab syringes.
Related Concept Videos
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
01:13Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
01:19Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...
01:23Ophthalmic Drug Delivery Systems
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
01:28Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices
Parenteral drug delivery systems play a crucial role in modern therapeutics by enabling the direct administration of drugs into the systemic circulation, bypassing the gastrointestinal tract. These systems are particularly valuable for poorly absorbed oral medications that are unstable in the digestive environment or require rapid onset or sustained therapeutic levels. Delivery is achieved through intravenous, intramuscular, or subcutaneous routes, each selected based on the drug's properties...
01:30Modified-Release Drug Delivery Systems: Bioavailability
Modified-release (MR) dosage forms are designed to extend drug release over time, thereby maintaining stable plasma concentrations and reducing dosing frequency. However, their bioavailability is typically below 100% due to incomplete drug release and presystemic metabolism, and limitations in drug permeability across the gastrointestinal epithelium, all of which can restrict the fraction of the drug reaching systemic circulation. Consequently, studying the in vivo bioavailability of MR...